Dichloroacetate nanoparticles and doxorubicin combinatorial treatment augment the hepato-renal function in Ehrlich ascites carcinoma cells.

Amira T Khattab, Mai M El-Keiy, Doha M Beltagy, Maha M Salem

Abstract read

In one paragraph

Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amira T KhattabBiochemistry Department, Faculty of Science, Damanhour University, Damanhour, 22514, Egypt.

Mai M El-KeiyBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31257, Egypt.

Doha M BeltagyBiochemistry Department, Faculty of Science, Damanhour University, Damanhour, 22514, Egypt.

Maha M SalemBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31257, Egypt. maha_salem@science.tanta.edu.eg.ORCID http://orcid.org/0000-0002-9108-6932

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCancer cells are addressed through conventional chemotherapy, resulting in tumour resistance and systemic toxicities affecting organ functions. Nanoparticle (NPs) represent a promising approach to improve chemotherapeutic efficacy and reduce adverse effects. This study aims to improve hepato-renal function by dichloroacetate nanoparticles (DCA-PNPs) and doxorubicin (Dox) combinatorial treatment in Ehrlich ascites carcinoma (EAC) model.

resultsDichloroacetate nanoparticles characterizations showed effective drug encapsulation, optimal particles size, morphology, and distribution. Biochemical analysis showed normalized protein content, improved lipid profile, enhanced liver, kidney functions, antioxidant activity, and decreased oxidative-stress with Dox/DCA-PNPs combination treatment, indicating that NPs-based therapy enhanced therapeutic outcomes and minimized systemic toxicity via mitigated Dox side effects and maintained organ's function. This study elucidates that Dox/DCA-PNPs combination therapy provides a more effective strategy for EAC hepatorenal function improvements.

Indexed as

Carcinoma, Ehrlich TumorDichloroacetic AcidDoxorubicinKidneyLiverNanoparticlesAnimalsCell Line, TumorMaleMiceOxidative StressDichloroacetic AcidDoxorubicinCombination therapyDichloroacetate nanoparticlesDoxorubicinEACHepato-renal

Identifiers

PMID41233912

DOI10.1186/s13104-025-07534-3

PMCPMC12616949

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.